BHB810 in advanced gastric and GEJ cancer (early-phase)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1/2 interventional study evaluating BHB810 in adults with advanced gastric or gastroesophageal adenocarcinoma. Participants receive intravenous BHB810 every 14 days to assess safety, dosing, pharmacokinetics, and preliminary efficacy. Phase 1 backfill cohorts and Phase 2 require CDH17 positivity by central testing, with additional biopsy requirements for tumor tissue. Eligible participants have progressed on or lack standard therapies and must have measurable disease by RECIST 1.1. Exclusion criteria include prior cancer treatments defined in the protocol as incompatible with enrollment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.

  * Participants in Phase 1 Backfill Cohorts \& Phase 2 must be CDH17-positive by central testing.
  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
* Adequate organ and marrow function as defined in the protocol

Exclusion Criteria:

* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:

  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks
  * Immune checkpoint inhibitors within 4 weeks
  * Wide-field radiation therapy (\>30% marrow-bearing bones) within 4 weeks or \< 2 weeks of focal palliative radiation to nontarget lesions
* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
* Known hypersensitivity or allergic reaction to BHB810 or it's excipients
* Left ventricular ejection fraction \<50% or history of congestive heart failure Class III/IV
* QTc interval \> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.

Where it's running

• City of Hope Duarte
  Duarte, California, United States Recruiting
• NEXT Virginia
  Fairfax, Virginia, United States Recruiting
• University of California at Los Angeles
  Santa Monica, California, United States Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors

  This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.

  Recruiting at 23 sites Phase 1 IDEAYA Biosciences · Goodyear, Arizona and 22 other locations · NCT07277413

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Gastric and pancreatic cancer patients see if IR199 with Ga-68 and I-131 is safe and how it distributes in the body

  This study tests the safety and how the radio-labeled IR199 distributes in the body of adults with Claudin 18.2-positive gastric or pancreatic cancer.

  Recruiting Early Phase 1 Huashan Hospital · Shanghai · NCT07707531

• Perioperative HLX10 (serplulimab) with SOX chemotherapy for PD-L1 positive gastric/GEJ cancer

  This study tests whether adding HLX10 (serplulimab) to the SOX chemotherapy before and after surgery helps people with PD-L1 positive, locally advanced gastric or GEJ cancer compared to SOX alone.

  Recruiting at 5 sites Phase 2 National Cancer Center, Japan · Chiba, Chiba and 17 other locations · NCT07699939

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.